Oncology Investigators Provide Perspectives on the Prevention and Management of Tumor Lysis Syndrome


TumorLysis17

Interview with William G Wierda, MD, PhD

Track 1: Case: A 28-year-old man with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia starts induction hyper-CVAD and dasatinib
Track 2: Diagnostic criteria and identification of patients at risk for tumor lysis syndrome (TLS)
Track 3: Clinical care of patients at high risk for TLS
Track 4: Allopurinol for hyperuricemia in patients at lower risk for TLS
Track 5: Rasburicase for patients at higher risk for TLS
Track 6: Correlation between bulk of disease and clinical course of TLS
Track 7: TLS-associated renal failure
Track 8: Case: A 60-year-old man with previously untreated Stage III trisomy 12 chronic lymphocytic leukemia (CLL) harboring an IGHV gene mutation receives FCR and prophylactic allopurinol
Track 9: Relationship between renal function and risk of TLS
Track 10: Management of anti-CD20 antibody-related infusion reactions
Track 11: Infrequency of TLS in solid tumors
Track 12: Gradual dose escalation with venetoclax to mitigate the risk of TLS
Track 13: TLS as an on-target effect of venetoclax in CLL
Track 14: Investigational strategies combining venetoclax with other agents in CLL
Track 15: Tolerability of venetoclax in CLL
Track 16: Complementary activity of venetoclax and ibrutinib
Track 17: Case: A 70-year-old patient with previously treated CLL and 17p deletion experiences disease progression and receives venetoclax
Track 18: Risk stratification for TLS in patients initiating treatment with venetoclax
Track 19: Creatinine clearance as a modifier of TLS risk
Track 20: Algorithm for patients at high risk for TLS who are initiating venetoclax treatment
Track 21: Approach for patients at medium risk for TLS who are initiating venetoclax treatment
Track 22: Use of venetoclax in lieu of ibrutinib in patients with atrial fibrillation who are receiving anticoagulation treatment
Track 23: Rates of ibrutinib discontinuation due to toxicity
Track 24: Restarting dose escalation of venetoclax after a treatment hold
Track 25: Case: A 72-year-old patient with previously treated CLL and a low creatinine clearance receives salvage venetoclax
Track 26: Potential for fixed-duration or endpoint-based treatment with venetoclax in CLL
Track 27: Case: A 62-year-old patient with CLL and a low risk of TLS initiates dose-escalation treatment with venetoclax
Track 28: Transforming CLL into a chronic disease like chronic myeloid leukemia (CML)
Track 29: Role of chimeric antigen receptor (CAR) T-cell therapy in CLL
Track 30: CAR T-cell therapy-associated neurotoxicity

Interview with Amit Lahoti, MD

Track 1: Incidence of TLS in patients receiving CAR T-cell therapy
Track 2: Pathophysiology of TLS
Track 3: Monitoring renal function in patients at risk for TLS
Track 4: Case: A 46-year-old man with metastatic melanoma and chronic renal disease experiences TLS after initiating nanoparticle albumin-bound (nab) paclitaxel
Track 5: Renal-associated toxicities in patients receiving immune checkpoint inhibitors
Track 6: Differing mechanisms of action of allopurinol and rasburicase
Track 7: Dosing, administration and tolerability of rasburicase
Track 8: Clinical consequences of hyperkalemia
Track 9: Supportive measures for patients experiencing hyperkalemia
Track 10: Case: A 74-year-old man with relapsed/refractory CLL receives venetoclax/ibrutinib and TLS prophylaxis on a clinical trial
Track 11: Case: A 74-year-old man with transformed acute myeloid leukemia experiences TLS despite prophylaxis with allopurinol
Track 12: Case: A 60-year-old man with high-risk multiple myeloma and renal failure develops TLS after treatment with carfilzomib/pomalidomide/dexamethasone
Track 13: Management of hyperleukocytosis in patients with CML and a low baseline risk of TLS
Track 14: Use of uricosuric medications in patients with elevated uric acid levels
 
FACULTY:
 
William G Wierda, MD, PhD
DB Lane Cancer Research
Distinguished Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas
 
Amit Lahoti, MD
Associate Professor
Department of Nephrology
Division of Internal Medicine
The University of Texas
MD Anderson Cancer Center
Assistant Professor
Department of Internal Medicine
Baylor College of Medicine
Instructor, Division of Internal Medicine
The University of Texas
Medical School at Houston
Houston, Texas
 
EDITOR:
Neil Love, MD
Research To Practice
Miami, Florida